GOUR MEDICAL SA announced today that it has entered into an exclusive license agreement with IDEXX Laboratories, Inc. to continue the development of a recombinant monoclonal antibody for therapeutic use: anti-IgE chimeric antibody for the treatment of canine allergy.
December 21st, 2015
ZUG, Switzerland – Gour Medical SA, a veterinary biomedical company, announced today the signing of an agreement with IDEXX Laboratories, Inc. for the development of a therapeutic recombinant monoclonal antibody for use in dogs.
Gour plans to continue the development of a therapeutic recombinant dog-specific monoclonal antibody and to launch it in the market. A first product is under development for the treatment and prevention of atopic dermatitis in dogs, a substantial unmet medical need.
As a first step, Gour plans to conduct a proof-of-concept study to establish the efficacy of the dog specific recombinant antibody in this indication.
Gour Medical SA
Serge Goldner, CEO
+41 435 08 00 72 – Contact Here
Download Press Release document : PR_Gour Medical_Idexx Lab license agreement FINAL